Blood pressure medication recalls: what you need to know now
Several recent recalls involve blood pressure medications because some tablets may not dissolve properly or may carry other risks. The Macleods Pharma recall is the latest high‑profile example, but readers should view it in the broader landscape of concurrent recalls affecting similar medicines. This article explains what the Macleods recall means, how to check your bottles, what actions to take, and how it fits with other recent recalls.
Broader recall context: what else has recently happened
Beyond the Macleods action, other recalls have impacted blood pressure drugs for similar or different reasons. For example, Novartis issued a valsartan recall tied to dissolution testing concerns, and Pfizer has recalled a blood pressure medicine over concerns about a possible carcinogen. Inventia Healthcare also recalled chlorthalidone tablets due to dissolution testing failures. These events illustrate a pattern of ongoing quality-control issues in cardiovascular medications and highlight why patients should verify their specific medicine and batch details during recalls. Some outlets note that brand-name Tribenzor is not recalled, even when the generic combination (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) is.
Macleods Pharma USA recall: what’s affected and when
The recall covers two lots of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets, a generic combination used to treat high blood pressure. Specifically, 3,528 bottles of 30-count tablets from lot 12251163A are recalled, along with 216 bottles of 90-count tablets from lot 12251163B. Both lots expire on May 31, 2027. The recalled products have NDC numbers 33342-246-07 (30-count bottles) and 33342-246-10 (90-count bottles).
The FDA classified this action as a Class II recall, meaning the product may cause temporary or medically reversible health problems, but serious health consequences are unlikely. The underlying reason for the recall is “failed dissolution specifications,” meaning the pills did not dissolve as required during testing. Macleods Pharma USA began the recall on October 7, and the FDA classified it on October 26; distribution is nationwide and ongoing.
Brand-name context: Tribenzor vs. the recalled generic
Readers may know this medication by the brand name Tribenzor. It’s important to clarify that the brand-name Tribenzor is not recalled; the recall applies to the generic olmesartan medoxomil/amlodipine/hydrochlorothiazide combination. If you’re unsure whether your product is the generic or brand-name version, verify the exact product you have and check it against recall notices.
Other recent recalls worth knowing about
To give a fuller picture of the current recall landscape, it’s helpful to note that other recalls have occurred around similar drugs. For example, Inventia Healthcare Ltd. recalled 13,567 bottles of 25 mg chlorthalidone tablets after dissolution testing failures. In the novembre/august timeframe, a Novartis valsartan recall (Diovan) was issued for a dissolved specification issue in a different lot. Separately, a Pfizer recall concerned a blood pressure medication under three names due to potential carcinogen concerns. While these recalls involve different products and risks, they collectively signal the importance of checking your exact lot and confirming whether your medicine is affected.
What the recall means for risk and what to do next
The primary practical risk described in the Macleods recall is that the medication may not deliver the intended dose, potentially leading to insufficient blood pressure control. In plain terms: you should monitor your blood pressure and contact your doctor if readings are consistently high or you notice any concerning symptoms.
Because this is a Class II recall, the FDA generally considers continued use acceptable until a replacement is arranged, but you should consult your doctor before making changes to your medication routine. If you are affected, do not abruptly stop taking your medicine; instead, work with your healthcare provider to determine a replacement and a plan for safe transition.
How to check if your bottle is affected
Start by examining your prescription bottle for three key identifiers: the medicine name, the lot number, and the expiration date. For the Macleods recall, match the following specifics to your bottle: lot 12251163A (3,528 bottles, 30-count, NDC 33342-246-07, exp 05/31/2027) or lot 12251163B (216 bottles, 90-count, NDC 33342-246-10, exp 05/31/2027).
The lot number is typically printed on the side or bottom of the prescription label, and the lot may be labeled as “LOT” or simply as Lot. If your bottle matches either lot number, it is part of the recall and you should contact your pharmacist or healthcare provider for guidance on next steps and potential replacement options.
Actionable steps if your medication is recalled
First, contact your pharmacist or healthcare professional for guidance. Do not stop taking the medication abruptly unless your doctor instructs you to do so, as stopping suddenly can carry its own risks. Ask about a replacement and follow any instructions for returning or disposing of the recalled medication. If you experience concerning symptoms or readings, seek medical care promptly. If you have already taken a dose, maintain communication with your doctor about monitoring your blood pressure, as the risk is more about potential loss of efficacy than immediate toxicity.
To obtain current recall details, you can consult the FDA recall resources and your pharmacist for the most up-to-date guidance. In addition, if you are looking for practical returns or replacement steps, your pharmacy can advise on the process and any costs involved.
Timeline and scale: why timeliness matters
The Macleods recall began on October 7, with the FDA classifying it on October 26. Although the affected bottles number in the low thousands, this recall is set against a backdrop of millions of people who take blood pressure medications. Understanding both the initiation dates and the scale helps you gauge your own risk and urgency. The inclusion of multiple recalls in nearby timeframes—such as the Novartis and Pfizer actions—underscores the importance of confirming your product against current recalls and staying in touch with your clinician throughout the transition process.
Recalls at a glance (selected recent actions)
| Recall | Product | Recall Reason | Company | Dates | Notes |
|---|---|---|---|---|---|
| Macleods Macleods Pharma USA recall | Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide tablets | Failed dissolution specifications | Macleods Pharma USA | Initiated Oct 7; FDA classification Oct 26 | 3,528 bottles of 30-count (Lot 12251163A, NDC 33342-246-07) and 216 bottles of 90-count (Lot 12251163B, NDC 33342-246-10); exp 05/31/2027 |
| Inventia chlorthalidone recall | Chlorthalidone 25 mg tablets | Failed dissolution testing | Inventia Healthcare Ltd. | Date not specified in this article; recall reported after September testing | 13,567 bottles affected |
| Novartis valsartan recall (Diovan) | Valsartan (Diovan) tablets, lot AV5913C | Failed dissolution specifications | Novartis | Initiated Aug 4 | 90 x 160 mg tablets, exp June 2027; manufactured by Pantheon Manufacturing Services |
| Pfizer recall for potential carcinogen | Blood pressure medication (multiple names) | Possible carcinogen concerns | Pfizer | Dates vary by name and notice | Not detailed in this article; follow FDA/CNN for specifics |
Note: Brand-name Tribenzor remains not recalled; the recall concerns the generic combination product.
Bottom line for patients
If you’re taking a blood pressure medicine and you’re unsure whether you’re affected, treat the situation as you would with any recall: verify the exact product and lot number on your bottle, compare with recall notices, and consult your pharmacist or physician before making any changes. The overarching message is not to panic or abruptly discontinue therapy without professional guidance. The broader recall landscape reinforces the value of timely checks against recall data and a clear plan with your healthcare team for safe replacement and ongoing blood pressure management.